An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling
Investigative Ophthalmology & Visual Science · 2026
DOI: 10.1167/iovs.67.3.47 ↗At a glance
Journal article in Investigative Ophthalmology & Visual Science, 2026. Written by Chenfei Yan and 7 co-authors. Institution: Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, People's Republic of China. Major MEDLINE topics: DNA-(Apurinic or Apyrimidinic Site) Lyase, Retinal Neovascularization, Fibroblast Growth Factor 2. 55 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Purpose
Retinal neovascular (RNVs) diseases are major causes of visual loss. Current first-line therapies for RNV primarily target VEGF. However, intrinsic or acquired resistance to anti-VEGF therapy, along with the risks associated with repeated intraocular injections, underscores the need for alternative targets and new therapeutic strategies. Apurinic/apyrimidinic endonuclease 1 (APE1) regulates transcription factors implicated in RNV. The purpose of this study was to evaluate APE1 as a therapeutic target, assess the potential of its redox inhibitor, Refi-10, as a drug candidate for vascular retinopathies, and elucidate underlying mechanisms.
Methods
An oxygen-induced retinopathy (OIR) mouse model and the APE1 redox inhibitor Refi-10 were used to investigate the contribution of APE1 redox function in retinopathy neovascularization and assess the therapeutic efficacy of Refi-10. Transcriptomic analysis of OIR retinas identified pro-angiogenic factors and pathways associated with RNV and Refi-10-mediated improvement. Retinal pigment epithelium (RPE) and human retinal microvascular endothelial cells (hRMECs) were used to investigate cellular mechanisms and responses to Refi-10.
Results
Refi-10 significantly reduced pathological angiogenesis and ameliorated RNV disease. Mechanistic studies showed that Refi-10 attenuated inflammation and angiogenesis via APE1 inhibition. Notably, Refi-10 did not decrease retinal VEGF in OIR but mitigated RNV by suppressing fibroblast growth factor 2 (FGF2) expression.
Conclusions
These findings nominate APE1 and FGF2 signaling as promising therapeutic targets, and show that Refi-10 holds potential as a drug candidate for vascular retinopathies, offering an alternative or complementary approach to VEGF inhibition.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Ophthalmology, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
- School of Basic Medical Sciences, Shandong University, Jinan, People's Republic of China.
- National Health Commission Key Laboratory of Otorhinolaryngology, Qilu Hospital of Shandong University, Jinan, People's Republic of China.
Cite
APA
Yan, C., Fu, Q., Wang, J., Fan, Q., Xu, H., Zhang, R., Yuan, Y., & Li, J. (2026). An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling. Investigative Ophthalmology & Visual Science. https://doi.org/10.1167/iovs.67.3.47
Vancouver
Yan C, Fu Q, Wang J, Fan Q, Xu H, Zhang R, et al. An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling. Investigative Ophthalmology & Visual Science. 2026. doi:10.1167/iovs.67.3.47
BibTeX
@article{Yan2026,
author = {Yan, Chenfei and Fu, Qiangqiang and Wang, Jiawei and Fan, Qian and Xu, Haoran and Zhang, Rui and Yuan, Yan and Li, Jianqiao},
title = {An APE1 Redox Inhibitor Attenuates Pathological Retinal Vascularization by Suppressing FGF2 Angiogenic Signaling},
journal = {Investigative Ophthalmology & Visual Science},
year = {2026},
doi = {10.1167/iovs.67.3.47}
}
EUVIMED